Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?
Related Questions
What is your experience with transesophageal lung mass biopsies?
Would you use immunotherapy in patients with HIV and a positive viral load?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?
In patients with IV NSCLC and EGFR mutation, is there a cutoff on the % of allele frequency that is considered to be too low to be actionable?
Is there any data on the safety or efficacy of combining osimertinib-based therapy with HER2-targeted treatment in patients with EGFR-mutant NSCLC and concurrent HER2-positive breast cancer?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?
Is there a biomarker for which patients benefit from tarlatamab?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
